RE: SGC21 Oct 2025 12:20
Thanks for sharing worth a repeat :
Jigsaw pieces coming together nicely - one step at a time . Avacta have a masterplan , still a few more pieces to be announced this year .
Gmcc
-------
"The Quiet Catalyst Hidden in Plain Sight
SGC, You Elusive Little Minx ; Small Tumour, Big Turning Point
Salivary gland cancer (SGC) isn’t just a cohort buried in the #ESMO data, but the hinge turning #AVCT’s science into inflection. With fewer than 10,000 new U.S cases a year, it sits squarely within the FDA’s orphan threshold; a setup that opens doors to faster review, market exclusivity, and meaningful leverage for value creation.
The real power lies not in the paperwork.. but in the outcome that proves the platform’s worth. SGC has no standard of care, no targeted therapies, and a bleak 3-4 month median PFS on doxorubicin.
That’s what makes faridoxorubicin’s showing so disruptive: fourfold dose tolerance, zero severe cardiac events, and PFS already more than doubled. In a cancer this neglected, not incremental to say the least it’s paradigm shifting.
And it matters because regulators have played this hand before. Orphan indications with undeniable survival gains have a way of fast tracking through the FDA’s gates, usually within 6 to 12 months once the data leave no room for doubt. Think Keytruda’s tissue agnostic leap or Enhertu’s HER2 low expansion, those quiet pivots where mechanism trumped tumour type. The FDA rewards outcomes, yes, but even more so understanding, favouring therapies that demonstrate why they work, not just where they land.
SGC gives #AVCT something every biotech craves: a clear, winnable path where efficacy can’t be debated. Once proven, the mechanism expands because a drug that works in FAPlow, chemo resistant tissue doesn’t stop at rare disease. It sets the foundation for broader solid tumours, where the same tumour activation logic applies breast, pancreatic, ovarian, sarcomas each now faster, cheaper, and lower risk to validate. A step that opens the floodgate to mainstream oncology, and platform value starts accumulating across indications.
If you’re wondering where the rerating begins, it’s right here, in the quietest cohort of all.. 🦊
Last edited
12:49 AM · Oct 21, 2025
·
5,054
Views"
Sign In
Follow the stocks
